Predictors of Response to Olaparib: Looking beyond BRCA

Breast cancers can be caused by mutations in genes involved in DNA repair, most notably BRCA 1 & 2. PARP inhibitors are effective in BRCA-related cancers because they specifically target cells deficient in DNA repair—and are thought to be efficacious in other genes involved in DNA repair. A Penn Center for Precision Medicine Accelerator Fund recipient in 2017, Payal Shah, MD, provides an overview of an ongoing clinical trial at Penn Medicine to investigate the PARP inhibitor olaparib in cancers due to mutations in non-BRCA DNA repair genes. Dr. Shah is affiliated with the Rena Rowan Breast Center at Penn Medicine, where she is an Assistant Professor of Medicine in the Assistant Professor of Medicine in the Division of Hematology/Oncology.

Related Links

Personalized Diagnostics for Hematologic and Solid Tumor Cancers

Dr Shah’s Profile


July 19, 2017

Created by

Penn Physician VideoLink